StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CPRO.JK$50.00+0.00%
Fair $50.00+0.0%

CPRO.JK

PT Central Proteina Prima Tbk

Consumer Defensive / Farm ProductsJakarta

$50.00

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $50.00Fund rank 31/100 · Data gapFallback financials|
SA 47/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $206.3B · quality 57.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 51/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · CPRO.JKLocal privado en este navegador · PT Central Proteina Prima Tbk
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.98T

P/E

8.2x

↓

EV/EBITDA

5.4x

↓

ROE

11.2%

↑

Gross Margin

20.1%

↓

Debt/Equity

0.45

↑
52-Week Range$50
$50$88

TradingView lightweight chart

CPRO.JK price, volumen y niveles de valoración

Último $50.00Periodo -73.0%
Fair value: $50.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+6.5%

FCF CAGR

+6.1%

FCF margin

1.4%

FCF / Net income

0.33x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.95T · net income $423.65B · FCF $141.68B

2022-FY → 2025-FY

Gross margin

20.1%+0.1% pts

Operating margin

8.7%-1.3% pts

Net margin

4.3%-0.3% pts

FCF margin

1.4%-0.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$9947.12B$9947.12B$9280.24B$9027.28B$8242.34B
Net Income$423.65B$423.65B$319.98B$401.47B$373.67B
EBITDA$834.72B$834.72B$692.40B$779.36B$750.34B
EPS7.107.105.406.706.30
Gross Margin20.1%20.1%19.9%18.7%20.0%
Operating Margin8.7%8.7%8.8%8.4%10.0%
Net Margin4.3%4.3%3.4%4.4%4.5%
Balance Sheet
Debt/Equity0.450.450.480.630.74
Current Ratio1.131.13———
Cash Flow
Free Cash Flow$141.68B$141.68B$561.95B$206.33B$118.66B
Returns
ROE11.2%11.2%9.0%11.8%11.8%
Valuation
P/E8.208.209.267.768.41
EV/EBITDA5.435.436.646.647.23
P/B0.790.790.840.910.99
Growth & Yield
Revenue Growth7.2%7.2%2.8%9.5%—
EPS Growth31.5%31.5%-19.4%6.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-14.5%

fácil

EPS terminal req.

$4.44

Spread vs growth

46.0%

5Y implied EPS CAGR

-5.4%

fácil

EPS terminal req.

$5.37

Spread vs growth

36.9%

10Y implied EPS CAGR

2.0%

fácil

EPS terminal req.

$8.65

Spread vs growth

29.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -3.8%

Total return

-3.8%

Start / end P/E

9.6x → 7.0x

EPS bridge

5.40 → 7.10

Residual

-8.5%

EPS growth+31.5%
Multiple rerating-26.9%
Dividend+0.0%
Residual / FX / buybacks / cross-term-8.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.